Ryan Buffalo
Family Medicine · Heber Springs, ARNPI 1356330666
Payments from drug & device makers
Across 301 payments — averaging $14.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$719
- AstraZeneca$475
- Pfizer$426
- AbbVie$322
- Otsuka America Pharmaceutical, Inc.$309
- Amgen$293
- plus $2K from 24 others
What the payments were for
- Food & beverage$4,317100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 84 | $719 |
| AstraZeneca | 22 | $475 |
| Pfizer | 26 | $426 |
| AbbVie(2 entities) | 25 | $322 |
| Otsuka America Pharmaceutical, Inc. | 15 | $309 |
| Amgen | 20 | $293 |
| Astellas Pharma US Inc | 16 | $244 |
| Almatica Pharma LLC | 9 | $150 |
| Sumitomo Pharma America, Inc. | 10 | $142 |
| Boehringer Ingelheim | 9 | $131 |
| Abbott | 7 | $129 |
| Phathom Pharmaceuticals, Inc. | 8 | $118 |
| Merck | 5 | $84 |
| Novo Nordisk | 5 | $83 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $80 |
| Lilly USA, LLC | 5 | $75 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $74 |
| Lucid Diagnostics Inc. | 1 | $63 |
| Lundbeck LLC | 4 | $58 |
| Genentech USA, Inc. | 3 | $51 |
| E.r. Squibb & Sons, L.L.C. | 3 | $44 |
| Johnson & Johnson | 2 | $40 |
| Bayer | 2 | $34 |
| Verona Pharma, Inc. | 2 | $32 |
| Sunovion Pharmaceuticals Inc. | 2 | $32 |
| Exact Sciences | 2 | $29 |
| Idorsia Pharmaceuticals US Inc | 2 | $26 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
How this compares
$4,317 in reported general payments places this provider in the 80th percentile of 1,347 family medicine providers in Arkansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 258 | $232,439 |
| OzempicSemaglutide | 126 | $142,943 |
| EliquisApixaban | 141 | $140,262 |
| JardianceEmpagliflozin | 87 | $75,939 |
| MounjaroTirzepatide | 60 | $70,418 |
| LinzessLinaclotide | 62 | $35,400 |
| MyrbetriqMirabegron | 44 | $33,412 |
| FarxigaDapagliflozin Propanediol | 28 | $32,798 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 84 | $28,801 |
| JanuviaSitagliptin Phosphate | 35 | $27,791 |
| XareltoRivaroxaban | 33 | $26,993 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $21,095 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 167 | $20,916 |
| Aimovig AutoinjectorErenumab-Aooe | 18 | $20,602 |
| RexultiBrexpiprazole | 12 | $17,756 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $719 | $275,308327 claims |
| Novo NordiskOzempic | $83 | $142,943126 claims |
| PfizerEliquis | $426 | $140,262141 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $131 | $86,397100 claims |
| Lilly USA, LLCMounjaro | $75 | $70,41860 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $475 | $62,585106 claims |
| MerckJanuvia, Lagevrio (Eua) | $84 | $35,72954 claims |
| AbbVieLinzess | $322 | $35,40062 claims |
| Astellas Pharma US IncMyrbetriq | $244 | $33,41244 claims |
| Johnson & JohnsonXarelto | $40 | $26,99333 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $309 | $17,75612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in Heber Springs
- George KonisLittle Rock$26.6M
- Kevin RobertsLittle Rock$2.5M
- Derek LewisLittle Rock$1.7M
- Jodi SansonHot Springs$1.7M
- Senthil RaghavanLittle Rock$496K
- Broderick EatonWynne$442K
- Landon HumphreyConway$417K
- Vonda HouchinHarrisburg$206K
- Glenn GibbonsFort Smith$179K
- Christopher BrownJonesboro$160K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.